A new frontier in the treatment of schizophrenia

Abstract

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia

Kaul

Sawchak

Walling

Tamminga

Breier

Zhu

Miller

, and others. 2024. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 81:749–56. https://doi.org/10.1001/jamapsychiatry.2024.0785

Paul

Yohn

Brannan

Neugebauer

Breier

2024. Muscarinic receptors as novel treatments for schizophrenia. Biol Psychiatry 96:627–37. https://doi.org/10.1016/j.biopsych.2024.03.014

Theodoridou

Rössler

2010. Disease burden and disability-adjusted life years due to schizophrenia and psychotic disorders. In: Preedy

Watson

editors. Handbook of disease burdens and quality of life measures. New York (NY): Springer. p. 1493–507. https://doi.org/10.1007/978-0-387-78665-0_87